Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 25, 2023

Durvalumab vs Placebo With Chemoradiotherapy for Locally Advanced Cervical Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
Lancet Oncol 2023 Dec 01;24(12)1334-1348, BJ Monk, T Toita, X Wu, JC Vázquez Limón, R Tarnawski, M Mandai, R Shapira-Frommer, U Mahantshetty, M Del Pilar Estevez-Diz, Q Zhou, S Limaye, FJR Godinez, C Oppermann Kussler, S Varga, N Valdiviezo, D Aoki, M Leiva, JY Lee, R Sulay, Y Kreynina, WF Cheng, F Rey, Y Rong, G Ke, S Wildsmith, A Lloyd, H Dry, A Tablante Nunes, J Mayadev

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading